MetaCap

Arrowhead Pharmaceuticals (ARWR) vs Supernus (SUPN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arrowhead Pharmaceuticals (ARWR) has outperformed Supernus (SUPN) over the past year, gaining 2.3% versus a loss of 36.9%. Over five years, SUPN leads with a -6.5% price change compared with -42.6% for ARWR. Supernus is the larger company by market cap ($5.94 billion vs $5.85 billion), about 1.0 times the size.

Supernus converts more of its revenue into profit, with a net margin of -5.4% versus -160.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARWR+2.27%SUPN-36.87%
+130%+40%-50%
Nov 21, 20251 yearNov 20, 2026
ARWR-41.82%SUPN-14.52%
+72%-10%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARWR versus SUPN key metrics
MetricARWRSUPN
Share price$41.37$28.61
Market cap$5.85B$5.94B
1-day change-5.22%+0.92%
YTD return-37.69%-42.43%
1-year return+2.27%-36.87%
5-year return-42.56%-6.53%
Forward P/E—7.15
EPS (TTM)$-5.11$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$450.82M$718.95M
Revenue growth (YoY)-45.65%+8.63%
Net income (latest FY)$-724.21M$-38.55M
Gross margin—89.63%
Operating margin-156.86%-8.66%
Net margin-160.64%-5.36%
52-week high$95.49$42.81
52-week low$40.43$25.92
Distance from 52-week high-56.68%-33.17%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+156.39%+89.23%
Average volume2.08M2.77M
Shares outstanding141.37M207.72M
Employees1,062827
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARWR has outperformed SUPN by 39.1 percentage points over the past year.
  • Supernus is more profitable, keeping -5.4 cents of every revenue dollar as net income versus -160.6 cents for Arrowhead Pharmaceuticals.
  • Supernus grew revenue faster in its latest fiscal year (+8.63% vs -45.65%).

About Arrowhead Pharmaceuticals

ARWR stock →

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,062 employees

About Supernus

SUPN stock →

Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees

ARWR vs SUPN FAQ

Which is bigger, Arrowhead Pharmaceuticals or Supernus?

Supernus (SUPN) is larger, with a market capitalization of $5.94B compared with $5.85B for Arrowhead Pharmaceuticals (ARWR).

Which stock has performed better over the past year, ARWR or SUPN?

ARWR returned +2.27% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.

Are Arrowhead Pharmaceuticals and Supernus in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons